Living with Wilson A patient-led project
A 文 English

← Back to all answers

treatmentdaily-life

What happens if I miss a dose? Or stop for a while?

A single missed dose is rarely catastrophic. Sustained non-adherence (weeks to months) is dangerous and can lead to liver failure. If you have stopped, restart and contact your specialist immediately — do not wait for symptoms.

Written by the Living with Wilson team · Last reviewed 2026-04-26

Missing one dose

A single missed dose is a normal human event and not a crisis. Take the next dose at the next scheduled time. Do not double up to “make up for it.”

If you frequently forget doses, the issue is the dose schedule, not your willpower. Simple changes — pill organizer, alarm on phone, dose-around-meals routine — solve nearly all of it. Studies of adherence across chronic diseases consistently find that schedule complexity is one of the biggest modifiable barriers, and that practical reminders improve consistency.1

Missing several days

Missing 3–7 days is a problem but rarely catastrophic in someone whose disease has been well-controlled for years. Restart at your normal dose and let your specialist know at the next visit.

Stopping for weeks to months

This is the part that matters most: stopping treatment for weeks to months carries real, documented risks, especially for patients on chelation therapy (penicillamine or trientine). Both the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL) are explicit that Wilson disease requires lifelong, uninterrupted treatment.23

Reported consequences of prolonged treatment cessation include:

  • Acute liver decompensation — sometimes progressing to fulminant liver failure requiring emergency transplant. Cases of previously stable patients dying of acute liver failure within months of stopping medication are documented in the literature, occurring in settings that include pregnancy, depression, and a misguided belief that the disease had resolved.4
  • Hemolytic anemia — sudden destruction of red blood cells is a recognised feature of active copper accumulation and has occurred after treatment interruption.23
  • Neurological deterioration — reappearance or worsening of neurological symptoms can occur after stopping therapy, and some of that deterioration may not be fully reversible.5

Pregnancy is a particularly high-risk period for stopping

Some patients — and occasionally some non-specialist clinicians — assume that Wilson disease medication should be paused during pregnancy out of concern for the baby. This is almost always wrong. A large European registry study found that abrupt cessation of copper-reducing therapy during pregnancy is associated with acute liver failure, with outcomes that can be fatal for both mother and baby. Current guidance recommends continuing therapy throughout pregnancy, often at a lower dose, under specialist supervision.6

If you have stopped

If you are reading this because you have stopped your medication for any length of time:

  1. Do not wait for symptoms. Restart your medication today.
  2. Contact your specialist this week. Even a phone call or message — let them know.
  3. Get bloodwork. Liver enzymes, full blood count, ceruloplasmin, and a fresh 24-hour urine copper.
  4. Be honest with the team. Adherence problems are common across all chronic diseases — non-adherence rates of 30–50% have been reported in long-term conditions.1 Specialists who treat Wilson disease have seen this many times. The goal is not to hide it — the goal is to get you stable again.

Why people stop

Common reasons include side effects, cost, depression, denial, pill fatigue, and a feeling of “I feel fine, do I really need this?”

Depression deserves particular attention. Research across multiple chronic diseases confirms that depression is a significant independent risk factor for medication non-adherence, approximately tripling the odds of not taking treatment consistently.7 Wilson disease itself carries a higher burden of depression and psychiatric symptoms than the general population — these symptoms can be part of the disease, not a separate problem.8 If low mood or a sense of hopelessness is part of why you have stopped, that is important information for your care team.

A study of a real-world Polish cohort of Wilson disease patients found that treatment interruptions were common and were associated with worse long-term outcomes.9 The lesson is not that patients are careless — it is that this is hard, and that support matters.

For each barrier, there are workable answers: a different drug, a patient-assistance program, a mental-health referral, a frank conversation about your daily routine. Bring the real reason to your specialist; the alternatives are usually better than you think.

This page is for general patient education and does not constitute medical advice. Treatment decisions — including what to do if you have stopped your medication — should always be made with your own treating physician or specialist centre.

References

  1. DiMatteo, M. Robin, Heidi S. Lepper, and Thomas W. Croghan. “Depression Is a Risk Factor for Noncompliance With Medical Treatment: Meta-Analysis of the Effects of Anxiety and Depression on Patient Adherence.” Archives of Internal Medicine 160, no. 14 (2000): 2101–2107. https://doi.org/10.1001/archinte.160.14.2101. ↩↩

  2. Schilsky, Michael L., Eve A. Roberts, Jeff M. Bronstein, Anil Dhawan, James P. Hamilton, Anne Marie Rivard, Mary Kay Washington, and Karl Heinz Weiss. “A Multidisciplinary Approach to the Diagnosis and Management of Wilson Disease: 2022 Practice Guidance on Wilson Disease from the American Association for the Study of Liver Diseases.” Hepatology 82, no. 3 (2022): E41–E90. https://doi.org/10.1002/hep.32801. ↩↩

  3. European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Wilson’s Disease.” Journal of Hepatology 56, no. 3 (2012): 671–685. https://doi.org/10.1016/j.jhep.2011.11.007. ↩↩

  4. Alkhouri, Naim, Regino P. Gonzalez-Peralta, and Valentina Medici. “Wilson Disease: A Summary of the Updated AASLD Practice Guidance.” Hepatology Communications 7, no. 6 (2023). https://doi.org/10.1097/HC9.0000000000000150. ↩

  5. Litwin, Tomasz, Anna Członkowska, and Lukasz Smolinski. “Early Neurological Worsening in Wilson Disease: The Need for an Evidence-Based Definition.” Journal of Hepatology 79, no. 6 (2023): e241–e242. https://doi.org/10.1016/j.jhep.2023.06.009. ↩

  6. Pfeiffenberger, Jan, Sandra Beinhardt, Daniel N. Gotthardt, Nicole Haag, Markus Freissmuth, Ulrike Reuner, Andrea Gauss, et al. “Pregnancy in Wilson’s Disease: Management and Outcome.” Hepatology 67, no. 3 (2018): 1261–1269. https://doi.org/10.1002/hep.29490. ↩

  7. Zimbrean, Paula C., and Michael L. Schilsky. “Psychiatric Aspects of Wilson Disease: A Review.” General Hospital Psychiatry 36, no. 1 (2014): 53–62. https://doi.org/10.1016/j.genhosppsych.2013.08.007. ↩

  8. Członkowska, Anna, Tomasz Litwin, Petr Dusek, Peter Ferenci, Svetlana Lutsenko, Valentina Medici, Janusz K. Rybakowski, Karl Heinz Weiss, and Michael L. Schilsky. “Wilson Disease.” Nature Reviews Disease Primers 4, no. 1 (2018): 22. https://doi.org/10.1038/s41572-018-0024-5. ↩

  9. Maselbas, Wojciech, Tomasz Litwin, and Anna Czlonkowska. “Social and Demographic Characteristics of a Polish Cohort with Wilson Disease and the Impact of Treatment Persistence.” Orphanet Journal of Rare Diseases 14, no. 1 (2019): 167. https://doi.org/10.1186/s13023-019-1133-2. ↩

This is patient education, not medical advice. Always consult your own clinical team about decisions for your care.